Automated direct SLT demonstrates safety, efficacy in first human trial
LAS VEGAS — Automated direct selective laser trabeculoplasty appears to reduce IOP in patients with primary open-angle glaucoma, according to a speaker here.
“This initial trial demonstrated safety and a signal of efficacy,” Yoram Solberg, MD, PhD, said at the American Society of Cataract and Refractive Surgery meeting.
Solberg and colleagues conducted a prospective, single-arm, nonrandomized, masked clinical trial to evaluate automated direct SLT in 15 patients with primary open-angle glaucoma, ocular hypertension or pseudoexfoliation. The primary outcome measure was the mean percentage reduction in IOP from baseline to 3 months. Secondary outcomes included change from baseline to 6 months and change in number of medications from baseline to 6 months.
Patients had a 21.4% IOP reduction at 3 months (P < .05) and an 18.8% reduction at 6 months (P < .01). The mean number of hypotensive medications was 1.6 at baseline and 0.4 at 6 months.
There were no serious or sight-threatening adverse events, and there were four punctate “non-clinically significant subconjunctival hemorrhages,” Solberg said.
“The laser treatment takes about 2 seconds — that’s it. It’s very simple, and anyone actually can do it. You don’t need to be a glaucoma expert,” he said. “This calls for a confirmatory study.”
Enrollment in the GLAUrious trial concluded in April 2021, and primary endpoint results are anticipated in January 2022, Solberg said.
Editor's note: On July 26, 2021, this article was corrected to correctly identify Yoram Solberg, MD, PhD, as the speaker. Healio editors regret this error.
Collapse
Goldenfeld M. Automated direct selective laser trabeculoplasty: First-in-human prospective clinical study. Presented at: American Society of Cataract and Refractive Surgery meeting; July 23-27, 2021; Las Vegas.
Read more about